Related Experiment Videos
Integrated treatment of panic disorder
J F Rosenbaum1, R A Pollock, M W Otto
1Outpatient Psychiatry Division, Massachusetts General Hospital, Boston 02114-3139, USA.
Bulletin of the Menninger Clinic
|January 1, 1995
Summary
Panic disorder affects 3.5% of US adults, with 2-5% experiencing agoraphobia. Integrated treatments combining medication and therapy are recommended for this complex condition.
Area of Science:
- Psychiatry
- Clinical Psychology
Background:
- Panic disorder affects approximately 3.5% of US adults.
- Agoraphobia, with or without panic, impacts an additional 2-5% of the adult population.
- Both biological and behavioral models attempt to explain panic disorder and agoraphobia.
Purpose of the Study:
- To review current research on biological and behavioral models of panic disorder and agoraphobia.
- To examine existing pharmacological and cognitive-behavioral treatment strategies.
- To advocate for an integrated treatment approach for panic disorder and agoraphobia.
Main Methods:
- Literature review of epidemiological studies.
- Synthesis of research findings on etiological models.
- Analysis of treatment outcome studies for pharmacological and psychosocial interventions.
Main Results:
- Panic disorder and agoraphobia represent significant public health concerns in the United States.
- Multiple biological and behavioral factors contribute to the development and maintenance of these disorders.
- Current treatments include pharmacotherapy and cognitive-behavioral therapy, with varying degrees of efficacy.
Conclusions:
- The multifaceted nature of panic disorder and agoraphobia necessitates a comprehensive treatment strategy.
- Combination therapy, integrating pharmacotherapy with psychosocial interventions, shows promise for improved patient outcomes.
- Further research is needed to optimize integrated treatment protocols for panic disorder and agoraphobia.